VK 0214

Drug Profile

VK 0214

Alternative Names: MB-10866; VK 0214

Latest Information Update: 28 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Kennedy Krieger Institute; Viking Therapeutics
  • Class Antihyperlipidaemics; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Adrenoleucodystrophy

Most Recent Events

  • 09 Aug 2018 Viking Therapeutics plans a proof-of-concept study for Adrenoleucodystrophy in 2019
  • 09 Aug 2018 Viking Therapeutics plans to file an IND for a proof-of-concept study in Adrenoleukodystrophy in 2019
  • 23 Oct 2017 Pharmacodynamics and pharmacokinetic data from a preclinical trial in Adrenoleucodystrophy released by Viking Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top